stockrowTeva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
Follow TEVA
Alert me
Teva Pharmaceutical Industries Ltd. (TEVA) P/E ratio
As of 5 November 2026, Teva Pharmaceutical Industries Ltd. (TEVA) trades at a P/E ratio of 92.6×. Over the past ten years it has ranged from 0.0× (September 2025) to 1,648× (June 2017); the current reading is higher than 96% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 20.5× and above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 25.2× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 22.8× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 535× | 1,400.90% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 87.9× | 63.38% |
| Jun 2026 | 53.8× | 144.61% |
| Mar 2026 | 22.0× | (12.65%) |
| Dec 2025 | 25.2× | (21.50%) |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VTRS Viatris Inc. compare | n/m |
| ELAN Elanco Animal Health Incorporated compare | n/m |
| ZTS Zoetis Inc. compare | 13.4× |
| UTHR United Therapeutics Corporation compare | 19.7× |
| HLN Haleon PLC Sponsored ADR compare | 20.5× |
| NBIX Neurocrine Biosciences, Inc. compare | 23.0× |
| TAK Takeda Pharmaceutical Co. compare | 32.0× |
| RDY Dr. Reddy's Laboratories Ltd compare | 44.4× |
| TEVA Teva Pharmaceutical Industries Ltd. | 92.6× |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on TEVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement